BLA STNFDA APPROVED LABELING TEXT HIGHLIGHTS OF PRESCRIBING INFORMTION These highlights do not include all the information needed to use . Blepharospasm: 1.25 Units-2.5 Units into each of 3 sites per affec

First Page		Document Content
Date: 2010-10-19 16:45:26 Neurology Plastic surgery Botulinum toxin Botulism Dystonia Blepharospasm Spasmodic torticollis Spasticity Hyperhidrosis Lorazepam Migraine treatment Prevention of migraines		BLA STNFDA APPROVED LABELING TEXT HIGHLIGHTS OF PRESCRIBING INFORMTION These highlights do not include all the information needed to use . Blepharospasm: 1.25 Units-2.5 Units into each of 3 sites per affec Add to Reading List Source URL: www.accessdata.fda.gov Download Document from Source Website File Size: 1,84 MB Share Document on Facebook

	Summit sheds light on disorders abqjournal.comnews/summit-sheds-light-on-disorders.html Mike Bush / Journal Staff Writer .......................................................................................... DocID: 1pU0H - View Document
	CLIENT INFORMATION & MEDICAL HISTORY In order to provide you with the most appropriate treatment, we need you to complete the following questionnaire. All information is strictly confidential. PERSONAL INFORMATION Client DocID: 1prjO - View Document
	BLA STNFDA APPROVED LABELING TEXT HIGHLIGHTS OF PRESCRIBING INFORMTION These highlights do not include all the information needed to use . Blepharospasm: 1.25 Units-2.5 Units into each of 3 sites per affec DocID: 1nR51 - View Document
	DECEMBER 2015 \| THE MEDICAL REPUBLIC Australasian College of Cosmetic Surgery DocID: 1m8Gx - View Document
	PRESS RELEASE MERZ NEUROSCIENCES TO PRESENT KEY CLINICAL DATA AT THE ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY (AAN) DocID: 1a1Yq - View Document